Price (delayed)
$1.46
Market cap
$138.28M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.39
Enterprise value
$506.59M
Through scientific and clinical excellence, and a deep understanding of cholesterol biology, the experienced Lipid Management Team at Esperion is committed to developing new LDL-C lowering medicines that will make
There are no recent dividends present for ESPR.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.